Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Diagnostic testing services firms complete merger Feb. 26 following an 11-month delay due to Federal Trade Commission concerns that the deal would lead to higher prices for clinical lab service customers in Northern California. A consent order with the agency requires that Quest divest assets worth $4.5 mil. to LabCorp - including leases for 46 patient services centers and four contracts with physician groups in Northern California. The $827 mil. cash and stock purchase of Unilab by Quest was first announced in April 2002 (1"The Gray Sheet" April 8, 2002, p. 19)...

You may also be interested in...

Quest Diagnostics Spends $1.6 Bil. To Expand Presence In California, D.C.

Quest Diagnostics will control 12% of the $3.8 bil. California lab testing market following the acquisition of Unilab Corp. The $1.1 bil. deal was announced April 2, one day after Quest completed its $500 mil. cash acquisition of Amercian Medical Labs (AML)

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts